47 ud af 47 tidsskrifter valgt, ingen søgeord valgt, emner højest 7 dage gamle, sorteret efter nyeste først.
210 emner vises.
201
The Lipid Intensive Drug Therapy for Sepsis Phase II Pilot Clinical Trial
Guirgis, Faheem W.; Black, Lauren Page; Henson, Morgan; Bertrand, Andrew; DeVos, Elizabeth; Ferreira, Jason; Gao, Hanzhi; Wu, Samuel S.; Leeuwenburgh, Christiaan; Moldawer, Lyle; Moore, Frederick; Reddy, Srinivasa T.
Critical Care Medicine, 22.03.2024
Tilføjet 22.03.2024
Objectives: Low cholesterol levels in early sepsis patients are associated with mortality. We sought to test if IV lipid emulsion administration to sepsis patients with low cholesterol levels would prevent a decline or increase total cholesterol levels at 48 hours. Design: Phase II, adaptive, randomized pilot clinical trial powered for 48 patients. Setting: Emergency department or ICU of an academic medical center. Patients: Sepsis patients (first 24 hr) with Sequential Organ Failure Assessment greater than or equal to 4 or shock. Interventions: Patients meeting study criteria, including screening total cholesterol levels less than or equal to 100 mg/dL or high-density lipoprotein cholesterol (HDL-C) + low-density lipoprotein cholesterol (LDL-C) less than or equal to 70 mg/dL, were randomized to receive one of three doses of lipid emulsion administered twice in 48 hours or no drug (controls). The primary endpoint was a change in serum total cholesterol (48 hr – enrollment) between groups. Measurements and Main Results: Forty-nine patients were enrolled and randomized. Two patients randomized to lipid emulsion were withdrawn before drug administration. Data for 24 control patients and 23 lipid emulsion patients were analyzed. The mean change in total cholesterol from enrollment to 48 hours was not different between groups and was 5 mg/dL (sd 20) for lipid emulsion patients, and 2 mg/dL (sd 18) for control patients (p = 0.62). The mean changes in HDL-C and LDL-C were similar between groups. Mean change in triglycerides was elevated in lipid emulsion patients (61 mg/dL, sd 87) compared with controls (20 mg/dL, sd 70, p = 0.086). The 48-hour change in SOFA score was –2 (interquartile range [IQR] –4, –1) for control patients and –2 (IQR –3, 0) for lipid emulsion patients (p = 0.46). Conclusions: Administration of IV lipid emulsion to early sepsis patients with low cholesterol levels did not influence change in cholesterol levels from enrollment to 48 hours.
Læs mere
Tjek på PubMed
202
Cryptococcus neoformans: plant–microbe interactions and ecology
Magnus Hallas-Mølle, Meike Burow, Bernard Henrissat, Katja Salomon Johansen
Trends in Microbiology, 22.03.2024
Tilføjet 22.03.2024
While the opportunistic human pathogens Cryptococcus neoformans and Cryptococcus gattii are often isolated from plants and plant-related material, evidence suggests that these Cryptococcus species do not directly infect plants. Studies find that plants are important for Cryptococcus mating and dispersal. However, these studies have not provided enough detail about how plants and these fungi interact, especially in ways that could show the fungi are capable of causing disease. This review synthesizes recent findings from studies utilizing different plant models associated with the ecology of C. neoformans and C. gattii. Unanswered questions about their environmental role are highlighted. Overall, current research indicates that Cryptococcus utilizes plants as a substrate rather than harming them, arguing against Cryptococcus as a genuine plant pathogen. We hypothesize that plants represent reservoirs that aid dispersal, not hosts vulnerable to infection.
Læs mere
Tjek på PubMed
203
Datathons: fostering equitability in data reuse in ecology
The Datathon 2022 Consortium:, Stephanie D. Jurburg, María J. Álvarez Blanco, Antonis Chatzinotas, Anahita Kazem, Birgitta König-Ries, Doreen Babin, Kornelia Smalla, Victoria Cerecetto, Gabriela Fernandez-Gnecco, Fernanda Covacevich, Emilce Viruel, Yesica Bernaschina, Carolina Leoni, Silvia Garaycochea, Jose A. Terra, Pablo Fresia, Eva Lucía Margarita Figuerola, Luis Gabriel Wall, Julieta Mariana Covelli, Ana Carolina Agnello, Esteban Emanuel Nieto, Sabrina Festa, Lina Edith Dominici, Marco Allegrini, María Celina Zabaloy, Marianela Estefanía Morales, Leonardo Erijman, Anahi Coniglio, Fabricio Dario Cassán, Sofia Nievas, Diego M. Roldán, Rodolfo Menes, Patricia Vaz Jauri, Carla Silva Marrero, Adriana Montañez Massa, María Adelina Morel Revetria, Ana Fernández-Scavino, Luciana Pereira-Mora, Soledad Martínez, Juan Pablo Frene
Trends in Microbiology, 22.03.2024
Tilføjet 22.03.2024
Approaches to rapidly collecting global biodiversity data are increasingly important, but biodiversity blind spots persist. We organized a three-day Datathon event to improve the openness of local biodiversity data and facilitate data reuse by local researchers. The first Datathon, organized among microbial ecologists in Uruguay and Argentina assembled the largest microbiome dataset in the region to date and formed collaborative consortia for microbiome data synthesis.
Læs mere
Tjek på PubMed
204
[Editorial] EU elections: a moment for pan-European health
The Lancet
Lancet, 22.03.2024
Tilføjet 22.03.2024
The past 5 years in Europe have been characterised by crisis. Long-standing Euroscepticism culminated in the UK\'s exit of the EU in 2020. Europe was unprepared for the COVID-19 pandemic, which pushed even the best health systems to their limits, resulting in the deaths of more than 1·1 million people in the European Union (EU). In 2022, peace in Europe ended abruptly with the Russian invasion of Ukraine. The war has so far killed more than 10 000 Ukrainian civilians, destroyed cities, and sparked mass migration, as well as precipitated an energy crisis across Europe.
Læs mere
Tjek på PubMed
205
[World Report] Pivotal tuberculosis vaccine trial begins
Talha Burki
Lancet, 22.03.2024
Tilføjet 22.03.2024
A phase 3 study of M72/AS01E has begun in South Africa, hoping to support the first new vaccine for tuberculosis since BCG. By Talha Burki.
Læs mere
Tjek på PubMed
206
[Perspectives] Andrew Kerkhoff: award-winning TB and HIV physician–scientist
Geoff Watts
Lancet, 22.03.2024
Tilføjet 22.03.2024
“What I like about being a physician–scientist is that when you see people every day in clinic, and you\'re reminded of immense need, you also know that through research you can design and implement solutions that help to address some of the challenges”, says Andrew Kerkhoff. As Assistant Professor in the Department of Medicine at the University of California, San Francisco (UCSF) and Zuckerberg San Francisco General Hospital, CA, USA, Kerkhoff is well placed to tackle the challenges posed by tuberculosis, the infection which, along with HIV, has been the focus of his career.
Læs mere
Tjek på PubMed
207
[Perspectives] Rendering deafness visible
Ruben E Verwaal
Lancet, 22.03.2024
Tilføjet 22.03.2024
“I\'m still reluctant to show my hearing impairment with pins and signs”, 66-year-old Henk van Rees admitted when he took part in one of my project focus groups. As part of this research I had organised online conversations about lived experiences of Deafness and hardness of hearing (DHH), with the support of speech-to-text and sign language interpreters. The participants in this particular group all used cochlear implants, but they recognised the desire to keep their hearing aids hidden from view.
Læs mere
Tjek på PubMed
208
[Articles] Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to
Magnus Ochoge, Ahmed Cherno Futa, Ama Umesi, Lucy Affleck, Larry Kotei, Baboucarr Daffeh, Ebrima Saidy-Jah, Anna Njie, Oluwafemi Oyadiran, Bassey Edem, Musa Jallow, Edrissa Jallow, Simon A Donkor, Erman Tritama, Talha Abid, Kathryn A V Jones, Bernardo A Mainou, John O Konz, Alan Fix, Chris Gast, Ed Clarke
Lancet, 22.03.2024
Tilføjet 22.03.2024
nOPV2 was immunogenic and safe in infants and young children in The Gambia. The data support the licensure and WHO prequalification of nOPV2.
Læs mere
Tjek på PubMed
209
[Seminar] Crohn's disease
Michael Dolinger, Joana Torres, Severine Vermeire
Lancet, 22.03.2024
Tilføjet 22.03.2024
Crohn\'s disease is a chronic inflammatory disease of the gastrointestinal tract that might lead to progressive bowel damage and disability. The exact cause of Crohn\'s disease is unknown, but evidence points towards multifactorial events causing dysregulation of the innate immune system in genetically susceptible people. Commonly affecting the terminal ileum and proximal colon, Crohn\'s disease inflammation is often discontinuous and patchy, segmental, and transmural. Identification of characteristic findings on ileocolonoscopy and histology remains the diagnostic gold standard, but complete assessment involves laboratory abnormalities, including micronutrient deficiencies, cross-sectional imaging to identify transmural disease extent, severity and complications, and a psychosocial assessment.
Læs mere
Tjek på PubMed
210
[Therapeutics] mRNA-based therapeutics: looking beyond COVID-19 vaccines
Hamideh Parhiz, Elena N Atochina-Vasserman, Drew Weissman
Lancet, 22.03.2024
Tilføjet 22.03.2024
Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA-encoded proteins, without the need to enter the nucleus or the risk of genomic integration, makes them desirable tools for treatment of a range of diseases, from infectious diseases to cancer and monogenic disorders. The rapid pace and ease of mass-scale manufacturability of mRNA-based therapeutics supported the global response to the COVID-19 pandemic.
Læs mere
Tjek på PubMed